On December 16, 2022, the FDA advised MAPS that the Partial Clinical Hold placed on our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2) would be continued due to “insufficient information to assess risks to human subjects.” MAPS is preparing a response to the the Clinical Hold issues and additional non-Clinical Hold issues the FDA has identified. Read the Continued Clinical Hold letter here.